Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550903 | 1.00 | FDFT1 (0.35) | FDFT1CHRNB2CHRNA4HDAC6CYP11B1 | |
| Water SCHEMBL28331546 | 0.98 | FDFT1 (0.34) | FDFT1CHRNB2CHRNA4HDAC6CYP11B1 | |
| SCHEMBL31065707 | 0.82 | FDFT1 (0.33) | FDFT1CHRNB2CHRNA4 | |
| SCHEMBL21404919 | 0.79 | FDFT1 (0.32) | FDFT1CHRNB2CHRNA4 | |
| SCHEMBL7995935 | 0.79 | FDFT1 (0.32) | FDFT1CHRNB2CHRNA4 | |
| SCHEMBL21405071 | 0.79 | FDFT1 (0.35) | FDFT1CHRNB2CHRNA4 | |
| SCHEMBL2004864 | 0.78 | FDFT1 (0.36) | FDFT1CHRNB2CHRNA4CYP11B1 | |
| SCHEMBL30955208 | 0.76 | NPC1 (0.42) | FDFT1CHRNB2CHRNA4 | |
| SCHEMBL18724653 | 0.76 | FDFT1 (0.35) | FDFT1CHRNB2CHRNA4CYP11B1 | |
| SCHEMBL4373548 | 0.76 | NPC1 (0.42) | FDFT1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026087899-A1 | MODULATORS OF THE GPR17 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2026-04-30 | — | — | WO | disclosed |
| EP-4568960-B1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| EP-4192823-B9 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | SANIONA AS (DK) | 2026-03-18 | — | — | EP | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4678641-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4192823-B1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | SANIONA AS (DK) | 2025-12-17 | — | — | EP | disclosed |
| EP-4655304-A1 | MACROCYCLIC AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2025-12-03 | — | — | EP | disclosed |
| EP-2566855-B1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-05-21 | — | — | EP | disclosed |
| US-8673894-B2 | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140045820-A1 | 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2657230-A1 | AMIDE DERIVATIVE AND USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| CN-103237800-A | Amide derivatives and use thereof | MITSUBISHI TANABE PHARMA CORP | 2013-08-07 | — | — | CN | disclosed |
| EP-2566855-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2013-03-13 | — | — | EP | disclosed |
| CN-102958922-A | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | HOFFMANN LA ROCHE | 2013-03-06 | — | — | CN | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| WO-2011138293-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211075-A1 | AMIDE DERIVATIVE AND USE THEREOF | IL2, IL4, IL5 | FDFT1 2950/4885CHRNB2 4537/4885CHRNA4 4143/4885 |
| US-20140045820-A1 | 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | BACE2, BACE1, PSEN2 | FDFT1 4017/4885CHRNB2 91/4885CHRNA4 253/4885 |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | FDFT1 4017/4885CHRNB2 91/4885CHRNA4 253/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | FDFT1 2909/4885CHRNB2 4706/4885CHRNA4 4815/4885 |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | FDFT1 4436/4885CHRNB2 2163/4885CHRNA4 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.